Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II, Open-label, Study of Intravitreal RAnibizumab 0.5MG, or High Dose 1.0mg for Retinal Vein Occlusions With rEfractory Macular Edema Previously Receiving iNtravitreal Bevacizumab (RAVEN)

NCT01471691 is registered in ClinicalTrials.gov with Hanscom, Thomas, M.D. as lead sponsor.

NCT NCT01471691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01471691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II, Open-label, Study of Intravitreal RAnibizumab 0.5MG, or High Dose 1.0mg for Retinal Vein Occlusions With rEfractory Macular Edema Previously Receiving iNtravitreal Bevacizumab (RAVEN)
Lead sponsor
Hanscom, Thomas, M.D.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2011
Completion date
February 28, 2014
Enrollment
14 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

branch retinal vein occlusion, central retinal vein occlusion, macular edema